Title:
FUSED TRICYCLIC CYCLIN-DEPENDENT KINASE INHIBITOR, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2022/166799
Kind Code:
A1
Abstract:
Provided are a fused tricyclic cyclin-dependent kinase inhibitor, and a preparation method therefor and a pharmaceutical use thereof. In particular, the structure of the fused tricyclic cyclin-dependent kinase inhibitor is shown in formula I, wherein substituents are defined in the description. The fused tricyclic cyclin-dependent kinase inhibitor is used for preventing and/or treating cyclin-dependent kinase related diseases, in particular cancers.
More Like This:
| WO/2010/083264 | NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS |
| WO/2018/138039 | CARBAZOLE DERIVATIVES |
| JP7166028 | Highly active STING protein agonist compounds |
Inventors:
LI YUNFEI (CN)
LIU HAOMIAO (CN)
ZOU HAO (CN)
ZHANG ZHEN (CN)
PANG XIAMING (CN)
GONG HONGLONG (CN)
ZHANG CHAO (CN)
ZHANG FANG (CN)
LIU HAOMIAO (CN)
ZOU HAO (CN)
ZHANG ZHEN (CN)
PANG XIAMING (CN)
GONG HONGLONG (CN)
ZHANG CHAO (CN)
ZHANG FANG (CN)
Application Number:
PCT/CN2022/074509
Publication Date:
August 11, 2022
Filing Date:
January 28, 2022
Export Citation:
Assignee:
TUOJIE BIOTECH SHANGHAI CO LTD (CN)
International Classes:
C07D487/06; A61K31/5383; A61P35/00; C07D401/14; C07D491/06; C07D498/06
Domestic Patent References:
| WO2018019204A1 | 2018-02-01 | |||
| WO2019207463A1 | 2019-10-31 | |||
| WO2019207463A1 | 2019-10-31 |
Foreign References:
| US20190330196A1 | 2019-10-31 | |||
| CN105164131A | 2015-12-16 | |||
| CN110234652A | 2019-09-13 | |||
| CN105189481A | 2015-12-23 | |||
| CN105294655A | 2016-02-03 | |||
| CN113698391A | 2021-11-26 |
Other References:
ANNU. REV. PHARMACOL. TOXICOL., vol. 39, 1999, pages 295 - 312
ANNU. REV. CELL. DEV. BIOL., vol. 13, 1997, pages 261 - 291
NATURE REVIEWS, vol. 13, 2016, pages 417 - 430
J CLIN ONCOL, vol. 35, 2017, pages 2875 - 2884
MALUMBRES ET AL.: "Mammalian Cells Cycle without the D-Type Cyclin-Dependent Kinases Cdk4 and Cdk6", CELL, vol. 118, no. 4, 2004, pages 493 - 504
SICINSKA ET AL.: "Essential Role for Cyclin D3 in Granulocyte Colony-Stimulating Factor-Driven Expansion of Neutrophil Granulocytes", MOL. CELL BIOL, vol. 26, no. 21, 2006, pages 8052 - 8060
COOPER ET AL.: "A unique function for cyclin D3 in early B cell development", NAT. IMMUNOL., vol. 5, no. 7, 2006, pages 489 - 497
ANNU. REV. CELL. DEV. BIOL., vol. 13, 1997, pages 261 - 291
NATURE REVIEWS, vol. 13, 2016, pages 417 - 430
J CLIN ONCOL, vol. 35, 2017, pages 2875 - 2884
MALUMBRES ET AL.: "Mammalian Cells Cycle without the D-Type Cyclin-Dependent Kinases Cdk4 and Cdk6", CELL, vol. 118, no. 4, 2004, pages 493 - 504
SICINSKA ET AL.: "Essential Role for Cyclin D3 in Granulocyte Colony-Stimulating Factor-Driven Expansion of Neutrophil Granulocytes", MOL. CELL BIOL, vol. 26, no. 21, 2006, pages 8052 - 8060
COOPER ET AL.: "A unique function for cyclin D3 in early B cell development", NAT. IMMUNOL., vol. 5, no. 7, 2006, pages 489 - 497
Attorney, Agent or Firm:
GE CHENG & CO., LTD (CN)
Download PDF: